| Israel | Türkei | Österreich | |
| Protonenstrahltherapie | von $48,000 | von $70,000 | von $80,000 |
| Chemotherapie bei Kehlkopfkrebs | von $620 | von $5,000 | von $12,000 |
| Strahlentherapie bei Kehlkopfkrebs | - | von $3,250 | von $6,890 |
| Laserchirurgie bei Kehlkopfkrebs | - | von $7,000 | von $15,000 |
| Laryngektomie | - | von $8,000 | von $25,000 |
Leiter der Abteilung für Weichteil- und Knochenonkologie am Sourasky Medical Center – Prof. Merimsky ist auf komplexe Sarkome und Kehlkopfkrebs spezialisiert.
Dr. Yuri Goldes ist Allgemeinchirurg mit über 20 Jahren klinischer Erfahrung. Er ist auf Chirurgie des oberen Gastrointestinaltrakts und onkologische Chirurgie spezialisiert. Er ist stellvertretender Direktor der Abteilung für Allgemeinchirurgie und Transplantation am Sheba Medical Center in Tel Aviv und leitet zudem die Einheit für obere GI-Chirurgie. 2025 wurde er in die Forbes-Israel-Liste der Best Doctors aufgenommen. Forbes führt ihn unter Israels besten Viszeralchirurgen. 2019 erhielt er die Auszeichnung „Arzt des Jahres“ des israelischen Gesundheitsministeriums.
Er ist Experte für fortgeschrittene minimalinvasive und robotische Chirurgie. Er behandelt Zwerchfellhernie, Achalasie, die gastroösophageale Refluxkrankheit (GERD) und Gallenblasenerkrankungen. Zudem führt er onkologische Eingriffe bei Pankreas-, Magen- und Speiseröhrenkrebs durch – laparoskopisch und robotisch.
Er führte einige der ersten robotischen onkologischen Resektionen von Magen und Pankreas in Israel durch. Weltweit gehört er zu einer kleinen Gruppe, die minimalinvasive Whipple-Operationen (Pankreatikoduodenektomie) mittels fortgeschrittener Laparoskopie durchführt. Er setzt Methoden ein, die Ergebnisse verbessern und die Genesung beschleunigen, und bietet individuelle Betreuung.
Dr. Orit Gutfeld ist eine führende Spezialistin für bösartige Tumore der HNO-Organe und leitet die Abteilung für Onkologie am Institut für Strahlentherapie des Sourasky Medical Center (Ichilov).
Prof. Dan Fliss, ein auf Kehlkopfkrebs spezialisierter Universitätsprofessor, leitet ein erstklassiges Onkologieprogramm am Sourasky Medical Center (Ichilov).
Israeli clinics specialize in organ-preserving larynx cancer treatments. Surgeons prioritize voice preservation through Transoral Laser Microsurgery (TLM). Advanced cases receive multidisciplinary care. This includes IMRT radiation, biological therapies, and robotic surgery. Facilities like Sourasky Medical Center report a 90% success rate for oncology treatments.
Bookimed Expert Insight: Israeli oncology centers like Sheba Medical Center and Hadassah operate as massive multidisciplinary hubs. These facilities manage between 1,000,000 and 2,000,000 patients every year. This massive volume allows surgeons like Dr. Thomas Shpitzer at Assuta to maintain high proficiency in rare, minimally invasive techniques. Patients benefit from this collective experience through highly refined rehabilitation protocols and speech preservation strategies.
Patient Consensus: Patients emphasize the need to discuss voice preservation early. Many note that speech and swallowing therapy are essential for a successful recovery after surgery.
Israeli specialized centers report a 90% success rate for larynx preservation in oncology patients. Surgeons prioritize advanced techniques like transoral laser microsurgery and robotic surgery. These methods remove tumors with high precision while sparing vocal cords and surrounding healthy tissue to maintain functional speech.
Bookimed Expert Insight: Data shows that choosing academic centers like Sourasky or Sheba provides a distinct advantage. These facilities perform over 34,000 to 45,000 operations annually across all departments. This high volume allows surgeons to maintain rare expertise in complex partial laryngectomies. Such procedures are vital for patients who do not qualify for laser surgery but still wish to avoid a total voice box removal.
Patient Consensus: Patients note that early-stage diagnosis is key for better voice outcomes. They emphasize finding a specialist who focuses specifically on head and neck oncology rather than general surgery.
Israeli hospitals report a 90% success rate for radiotherapy and surgical procedures in treating larynx cancer. The overall 5-year survival rate reaches 88% at major tertiary facilities. Early detection remains a critical factor. Approximately 82% of Israeli cases are diagnosed during localized stages.
Bookimed Expert Insight: Sourasky Medical Center maintains a 90% average success rate for oncology. This high performance correlates with clinics like Sheba and Sourasky serving over 400,000 patients annually. Large patient volumes allow surgeons to specialize deeply. For example, Dr. Yuri Goldes at Sheba is recognized for robotic surgical innovation. High-volume centers often provide better outcomes in complex organ-preserving surgeries.
Patient Consensus: Patients note that stage at diagnosis is the strongest predictor of survival outcomes. They emphasize the importance of requesting specific data on voice and swallowing quality post-treatment.
Israeli hospitals provide advanced surgical technologies for larynx cancer, including Transoral Robotic Surgery (TORS) and Transoral Laser Microsurgery (TLM). These techniques allow surgeons to remove tumors through the mouth. This avoids external incisions and preserves vital vocal functions. Leading centers often report success rates around 90%.
Bookimed Expert Insight: Israeli oncology centers demonstrate high integration between surgical technology and recovery. Centers like Sheba and Sourasky perform over 30,000 surgeries annually. They combine robotic precision with immediate voice rehabilitation. Dr. Yuri Goldes at Sheba pioneered robotic resections now used in complex cases. This volume-based expertise ensures that even complex reconstructions maintain high functional outcomes.
Patient Consensus: Patients note it is important to choose centers with on-site rehabilitation specialists. They appreciate how robotic tools helped them speak clearly soon after surgery.